Amado Rafael 4

4 · Zai Lab Ltd · Filed Mar 16, 2026

AI-generated summary of this filing

Updated Mar 16, 2026

Zai Lab (ZLAB) President Rafael Amado Sells 2,957 Shares

What Happened

Rafael Amado, President and Head of Global Oncology R&D at Zai Lab (ZLAB), received equity awards and had small disposal activity in early March 2026. On 2026-03-04 he was granted a total of 137,733 ADS-based awards (103,950 ADSs and 33,783 ADSs) as derivative awards/RSUs. On 2026-03-12 he exercised/converted 5,323 derivative shares (a portion of awards/options) and related shares were treated for tax/withholding purposes. On 2026-03-13 he sold 2,957 ADSs in the open market at $18.63 per ADS, netting $55,083. The sale was reported on a Form 4 filed 2026-03-16.

Key Details

Transaction dates and prices:
- 2026-03-04: Grants — 103,950 ADSs and 33,783 ADSs (awards/RSUs), $0 per share (derivative awards).
- 2026-03-12: Exercise/Conversion — 5,323 ADSs (derivative); exercise/conversion reported (disposition of 5,323 ADSs for tax/withholding purposes, $0 reported).
- 2026-03-13: Open-market sale — 2,957 ADSs at $18.63 each, proceeds $55,083.
Shares owned after the transactions: not specified in the filing.
Notable footnotes:
- F1: Each ADS represents 10 ordinary shares; filing reports in ADSs.
- F2–F4, F6–F7: Awards are RSUs (each RSU = right to one ADS); some vested ADSs were sold automatically to cover taxes. Vesting schedules vary (some awards vest annually over four years beginning 03/04/2027, others beginning 03/12/2026).
- F4 specifically states ADSs were sold automatically to cover taxes upon vesting.
Filing timeliness: Form 4 filed 2026-03-16 for transactions through 2026-03-13; filing does not indicate a late report.

Context

These filings show grant of long-term compensation (RSUs/derivatives) and routine tax-related disposals rather than a discretionary "sell for profit" trade. The automatic sale(s) and the reported $0 disposals reflect tax withholding/cashless treatment common when RSUs vest or options are exercised. Grants vest over multiple years per the footnotes, so most awarded shares are subject to future vesting and continued service.

Form 4

Period: 2026-03-04

See Remarks

Transactions

Exercise/Conversion
American Depositary Shares
[F1][F2][F3]
2026-03-12+5,323→ 47,714 total
Sale
American Depositary Shares
[F1][F4]
2026-03-13$18.63/sh−2,957$55,083→ 44,757 total
Award
Stock Options (Right to Buy)
[F5][F1]
2026-03-04+103,950→ 103,950 total
Exercise: $19.27Exp: 2036-03-04→ American Depositary Shares (103,950 underlying)
Award
Restricted Share Units
[F3][F6][F1]
2026-03-04+33,783→ 33,783 total
→ American Depositary Shares (33,783 underlying)
Exercise/Conversion
Restricted Share Units
[F3][F7][F1]
2026-03-12−5,323→ 15,971 total
→ American Depositary Shares (5,323 underlying)

Footnotes (7)

[F1]Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs.
[F2]ADSs acquired upon vesting of Restricted Share Units ("RSUs").
[F3]Each RSU represents a contingent right to receive one ADS.
[F4]These ADSs were sold automatically to cover taxes upon vesting of RSUs.
[F5]The option vests in equal annual installments over four years beginning on 03/04/2027, the first anniversary of the date of grant, subject to continuous service.
[F6]The RSUs vest in equal annual installments over four years beginning on 03/04/2027, the first anniversary of the date of grant, subject to continuous service. Vested shares will be delivered in the form of ADSs to the reporting person following vesting.
[F7]The RSUs vest in equal annual installments over four years beginning on 03/12/2026, the first anniversary of the date of grant, subject to continuous service. Vested shares will be delivered in the form of ADSs to the reporting person following vesting.

Signature

/s/ Bruce Blefeld, Attorney-in-Fact|2026-03-16

1 file